208 related articles for article (PubMed ID: 33342162)
1. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
[No Abstract] [Full Text] [Related]
2. Immunotherapy- A double Edged Sword; A case of Fatal Myocarditis and Complete Response.
Peters N; Greally M; Breen K; Fabre A; Blazkova S
Ir Med J; 2019 May; 112(5):937. PubMed ID: 31411390
[No Abstract] [Full Text] [Related]
3. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
[No Abstract] [Full Text] [Related]
4. Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer.
Tan JL; Mugwagwa AN; Cieslik L; Joshi R
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31300602
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
Callens R; Tamsin A; van Zandweghe L
J Thorac Oncol; 2019 Mar; 14(3):e49-e50. PubMed ID: 30782382
[No Abstract] [Full Text] [Related]
6. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
[TBL] [Abstract][Full Text] [Related]
8. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
Schouten RD; Muller M; de Gooijer CJ; Baas P; van den Heuvel M
Lung Cancer; 2018 Dec; 126():210-216. PubMed ID: 29179916
[No Abstract] [Full Text] [Related]
9. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
[TBL] [Abstract][Full Text] [Related]
10. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
Edahiro R; Shiroyama T; Hijiki S; Nojima S; Shirai Y; Koyama S; Kumanogoh A
Lung Cancer; 2020 Feb; 140():116-117. PubMed ID: 31848027
[No Abstract] [Full Text] [Related]
11. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
12. Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
Guaitoli G; Baldessari C; Tomasello C; Barbieri F; Cascinu S; Bertolini F; Cesinaro AM
J Thorac Oncol; 2018 Aug; 13(8):e152-e153. PubMed ID: 30049380
[No Abstract] [Full Text] [Related]
13. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
14. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.
Kim JS; Nam TS; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2019 Oct; 10(10):2045-2049. PubMed ID: 31436031
[TBL] [Abstract][Full Text] [Related]
16. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
[No Abstract] [Full Text] [Related]
17. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T
Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature.
Matsuo K; Ishiguro T; Najama T; Shimizu Y; Kobayashi Y; Mutou M
Intern Med; 2019 Aug; 58(16):2367-2372. PubMed ID: 31118387
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
